Open Access Research Article Molecular, Cellular and Physiological Characterization of the Cancer Cachexia-inducing C26 Colon Carcinoma in Mouse

Background: The majority of cancer patients experience dramatic weight loss, due to cachexia and consisting of skeletal muscle and fat tissue wasting. Cachexia is a negative prognostic factor, interferes with therapy and worsens the patients' quality of life by affecting muscle function. Mice bearing ectopically-implanted C26 colon carcinoma are widely used as an experimental model of cancer cachexia. As part of the search for novel clinical and basic research applications for this experimental model, we characterized novel cellular and molecular features of C26-bearing mice. Methods: A fragment of C26 tumor was subcutaneously grafted in isogenic BALB/c mice. The mass growth and proliferation rate of the tumor were analyzed. Histological and cytofluorometric analyses were used to assess cell death, ploidy and differentiation of the tumor cells. The main features of skeletal muscle atrophy, which were highlighted by immunohistochemical and electron microscopy analyses, correlated with biochemical alterations. Muscle force and resistance to fatigue were measured and analyzed as major functional deficits of the cachectic musculature. Results: We found that the C26 tumor, ectopically implanted in mice, is an undifferentiated carcinoma, which should be referred to as such and not as adenocarcinoma, a common misconception. The C26 tumor displays aneuploidy and histological features typical of transformed cells, incorporates BrdU and induces severe weight loss in the host, which is largely caused by muscle wasting. The latter appears to be due to proteasome-mediated protein degradation, which disrupts the sarcomeric structure and muscle fiber-extracellular matrix interactions. A pivotal functional deficit of cachectic muscle consists in increased fatigability, while the reported loss of tetanic force is not statistically significant following normalization for decreased muscle fiber size. Conclusions: We conclude, on the basis of the definition of cachexia, that ectopically-implanted C26 carcinoma represents a well standardized experimental model for research on cancer cachexia. We wish to point out that scientists using the C26 model to study cancer and those using the same model to study cachexia may be unaware of each other's works because they use different keywords; we present strategies to eliminate this gap and discuss the benefits of such an exchange of knowledge. Background Cancer genome projects are providing complete landscapes of the mutations that exist in tumors, making it essential to bridge the gap between high-throughput sequencing information and the molecular mechanisms

[1]  Jeffrey S. Damrauer,et al.  Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia , 2018, European journal of translational myology.

[2]  T. Nagykálnai,et al.  [Cachexia in cancer patients]. , 2016, Magyar onkologia.

[3]  H. Kern,et al.  Polymyositis, dermatomyositis and malignancy: a further intriguing link. , 2010, Autoimmunity reviews.

[4]  W. Evans,et al.  Skeletal muscle loss: cachexia, sarcopenia, and inactivity. , 2010, The American journal of clinical nutrition.

[5]  S. Merigliano,et al.  Subclinical myopathy in patients affected with newly diagnosed colorectal cancer at clinical onset of disease: evidence from skeletal muscle biopsies , 2010, Neurological research.

[6]  S. Gygi,et al.  During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation , 2009, The Journal of cell biology.

[7]  A. Pristerá,et al.  Modulation of Caspase Activity Regulates Skeletal Muscle Regeneration and Function in Response to Vasopressin and Tumor Necrosis Factor , 2009, PloS one.

[8]  D. Birnbaum,et al.  Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism , 2009, British Journal of Cancer.

[9]  A. Valencia,et al.  From cancer genomes to cancer models: bridging the gaps , 2009, EMBO reports.

[10]  J. Magyar,et al.  Orally Available Selective Melanocortin-4 Receptor Antagonists Stimulate Food Intake and Reduce Cancer-Induced Cachexia in Mice , 2009, PloS one.

[11]  J. Argilés,et al.  Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice , 2009, British Journal of Cancer.

[12]  M. Taketo,et al.  Mouse models of colon cancer. , 2009, Gastroenterology.

[13]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[14]  P. Vos,et al.  Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia , 2008, British Journal of Cancer.

[15]  Charles Giardina,et al.  Mouse models for the study of colon carcinogenesis. , 2008, Carcinogenesis.

[16]  Zhuangzhi Wang,et al.  A Novel Role for CD4+ T Cells in the Control of Cachexia1 , 2008, The Journal of Immunology.

[17]  A. Musarò,et al.  Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. , 2008, Human gene therapy.

[18]  A. Musarò,et al.  Measuring Mechanical Properties, Including Isotonic Fatigue, of Fast and Slow MLC/mIgf-1 Transgenic Skeletal Muscle , 2008, Annals of Biomedical Engineering.

[19]  Zhen Lu,et al.  Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down‐regulated in human ovarian cancers by loss of heterozygosity and promoter methylation , 2008, Cancer.

[20]  A. Pristerá,et al.  Tumor Necrosis Factor‐α Inhibition of Skeletal Muscle Regeneration Is Mediated by a Caspase‐Dependent Stem Cell Response , 2008, Stem cells.

[21]  F. Padula,et al.  Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice , 2008, Neurological research.

[22]  A. Goldberg,et al.  FoxO3 controls autophagy in skeletal muscle in vivo. , 2007, Cell metabolism.

[23]  K. Pienta,et al.  The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy , 2007, CA: a cancer journal for clinicians.

[24]  T. Rando,et al.  High Incidence of Non-Random Template Strand Segregation and Asymmetric Fate Determination In Dividing Stem Cells and their Progeny , 2007, PLoS biology.

[25]  D. Sassoon,et al.  Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. , 2006, Genes & development.

[26]  M. Grounds,et al.  Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx mice , 2006, Neuromuscular Disorders.

[27]  Justin M. Hicks,et al.  Text similarity: an alternative way to search MEDLINE , 2006, Bioinform..

[28]  N. Kaminski,et al.  Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. , 2006, Cancer research.

[29]  J. Encke,et al.  An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo , 2006, Journal of Gastrointestinal Surgery.

[30]  Laurens G. van der Flier,et al.  Mass‐dependent decline of skeletal muscle function in cancer cachexia , 2006, Muscle & nerve.

[31]  I. B. Borel Rinkes,et al.  Synergistic Effect of Interstitial Laser Coagulation and Doxorubicin in a Murine Tumor Recurrence Model of Solitary Colorectal Liver Metastasis , 2006, Annals of Surgical Oncology.

[32]  R. Schiffelers,et al.  Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer , 2006, Journal of liposome research.

[33]  J. Dipalma,et al.  U.S. practices for colon cancer screening. , 2005, The Keio journal of medicine.

[34]  Swarnali Acharyya,et al.  Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. , 2005, Cancer cell.

[35]  J. Sebolt-Leopold,et al.  A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. , 2005, Neoplasia.

[36]  Jeffrey S. Damrauer,et al.  Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. , 2004, The Journal of clinical investigation.

[37]  D. McCarthy,et al.  Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. , 2004, Research in nursing & health.

[38]  Y. Koyanagi,et al.  Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT , 2004, Cancer Gene Therapy.

[39]  A. Carè,et al.  Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis , 2004, Cancer Immunology, Immunotherapy.

[40]  Maria Laura Belladonna,et al.  Potent Antitumor Activity of Interleukin-27 , 2004, Cancer Research.

[41]  D. Wagener,et al.  Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model , 2004, Journal of Cancer Research and Clinical Oncology.

[42]  H. Yao,et al.  Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma. , 2003, Chinese medical journal.

[43]  G. Peters,et al.  Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma , 2003, British Journal of Cancer.

[44]  T. Sugimura,et al.  Enhancement of colon carcinogenesis by prostaglandin E2 administration. , 2003, Carcinogenesis.

[45]  H. Tanke,et al.  Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. , 2002, Cancer genetics and cytogenetics.

[46]  G. Diffee,et al.  Altered expression of skeletal muscle myosin isoforms in cancer cachexia. , 2002, American journal of physiology. Cell physiology.

[47]  M. Tisdale,et al.  Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. , 2000, Cancer research.

[48]  L. Ding,et al.  Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. , 1999, Cancer research.

[49]  H. Ishitsuka,et al.  Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma , 1999, British Journal of Cancer.

[50]  M. Monden,et al.  Anti‐interleukin‐6 receptor antibody prevents muscle atrophy in colon‐26 adenocarcinoma‐bearing mice with modulation of lysosomal and ATP‐ubiquitin‐dependent proteolytic pathways , 1996, International journal of cancer.

[51]  T. Partridge,et al.  Culturing satellite cells from living single muscle fiber explants , 1995, In Vitro Cellular & Developmental Biology - Animal.

[52]  M. Miyata,et al.  Characterization of Mice Bearing Subclones of Colon 26 Adenocarcinoma Disqualifies Interleukin‐6 as the Sole Inducer of Cachexia , 1994, Japanese journal of cancer research : Gann.

[53]  M. Burt,et al.  Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin. , 1993, Cancer research.

[54]  H. Ishitsuka,et al.  Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. , 1990, Cancer research.

[55]  L. Moldawer,et al.  Anticachectin/tumor necrosis factor‐α antibodies attenuate development of cachexia in tumor models , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  N. Sato,et al.  Characterization of tumorigenicity, mortality, metastasis, and splenomegaly of two cultured murine colon lines. , 1981, Cancer research.

[57]  F. Hirsch,et al.  Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. , 1980, Cancer research.

[58]  H. Kobayashi,et al.  Leukemoid reaction in BALB/c mice bearing primary tumors induced by 3-methylcholanthrene. , 1978, Cancer research.

[59]  F. Schabel,et al.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. , 1975, Cancer research.

[60]  S. Schastak,et al.  Initiation of apoptosis by photodynamic therapy using a novel positively charged and water-soluble near infra-red photosensitizer and white light irradiation. , 2008, Methods and findings in experimental and clinical pharmacology.

[61]  S. Adamo,et al.  Highlights on Cachexia, from the 4th Cachexia Conference, Tampa (FL), 6-9 Dec 2007 , 2008 .

[62]  M. Molinaro,et al.  Tumor necrosis factor-alpha gene transfer induces cachexia and inhibits muscle regeneration. , 2005, Genesis.

[63]  M. Latorre,et al.  ORIGINAL ARTICLES: Primary Malignant Epithelial Tumors of the Liver in Children: A Study of DNA Content and Oncogene Expression , 1998 .

[64]  D. Kiang,et al.  Reversal of myelofibrosis in advanced breast cancer. , 1978, The American journal of medicine.